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Accumulating evidence indicates that altered miRNA
expression is crucially involved in lung cancer develop-
ment, though scant information is available regarding how
MYC, an archetypical oncogene, is regulated by miRNAs,
especially via a mechanism involving MYC cofactors.
Although various oncogenes have thus far been identiﬁed
to be altered in various types of lung cancer, MYC is among
the most frequently ampliﬁed and overexpressed. The
MYC gene encodes a transcription factor that regulates a
wide variety of genes involved in control of cell growth,
proliferation, and apoptotic cell death. The transcriptional
activity of MYC is tightly controlled for proper transcrip-
tional regulation through various mechanisms, which
include MYC expression itself at both transcriptional and
posttranscriptional levels, as well as its interaction with
cofactors that functionally cooperate with MYC. Unfortu-
nately, very little is known thus far about how MYC is
regulated by miRNAs in lung cancer cells, especially via
the latter mechanism involving MYC cofactors.
In this study, we attempted to identify miRNAs
involved in regulation of MYC transcriptional activity in
lung cancer. To this end, we utilized an integrative
approach with combinatorial usage of miRNA and mRNA
expression proﬁle datasets of patient tumor tissues, as
well as those of MYC-inducible cell lines in vitro. Our re-
sults allowed us to identify multiple miRNAs reported as
either directly downstream or upstream of MYC, sup-
porting the robustness of our strategy. The former ex-
amples included the miR-17-92 cluster, miR-22, miR-26a,
miR-30a-3p, and miR-30e-3p, all of which were previ-
ously shown to be under MYC-mediated transcriptionalregulation, while the latter instances were comprised of
let-7, miR-34a and miR-24, which have been reported to
directly repress MYC expression via binding to a target
site at the 3’UTR of MYC. Intriguingly, our integrative
approach also led us to identify miR-342-3p, which we
found to be amiRNA indirectly regulatingMYC activity via
direct inhibition of E2F1, a MYC-cooperating transcrip-
tion factor. Furthermore, miR-342-3p module activity,
which we deﬁned as a gene set reﬂecting the experi-
mentally substantiated inﬂuence ofmiR-342-3p onmRNA
expression, was found to be inversely correlated with
MYC activity reﬂected by MYC module activity in 3 inde-
pendent datasets of lung adenocarcinoma patients. Our
present ﬁndings also clearly demonstrate that miR-342-
3p plays important roles to inhibit cell cycle progression
and proliferation in lung adenocarcinoma cell lines.
Taken together, our integrative approach appears to
be useful to elucidate inter-regulatory relationships be-
tween miRNAs and protein coding genes of interest, even
those present in patient tumor tissues, which remains a
challenge to better understand the pathogenesis of this
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Immunoproteasome are a specialized form of multi-
subunit complexes called proteasome that degrade
intracellular proteins through the ubiquitin-proteasome
pathway. It can generate peptides with high speciﬁcity
for binding onto MHC class I molecules, hence a
suitable candidate for CD8þ T cell mediated cytotoxic
responses. The expression of the immunoproteasome
and its impact on antigen presentation in tumors of
epithelial origin is not well established. We have
investigated the constitutive and induced expression
patterns of immunoproteasome subunits in non-small
cell lung cancer (NSCLC) and their consequence on
antigen presentation. We also assessed the impact of
immunoproteasome expression on survival in early
stage NSCLC.
February 2016 Abstracts S49Signiﬁcantly reduced expression of immunoprotea-
some components and their regulators was observed to
be associated with epithelial to mesenchymal transition
in 42 NSCLC cell lines using proteomic proﬁling and
microarray analysis. A highly variable immunopro-
teasome expression was also observed among NSCLC
tissues. Immunohistochemistry data revealed loss of
immunoproteasome subunit is signiﬁcantly correlated
with expression of CDH2 and concomitant loss of
CDH1 in NSCLC tumors. Loss of immunoproteasome
subunits was also signiﬁcantly associated with
advanced stage (p¼0.014), recurrence (p¼0.002) and
metastasis (p<0.01) in NSCLC patients. A signiﬁcantly
reduced antigen presentation was observed in
mesenchymal cell lines compared to epithelial cells.
Using mild acid elution, only 50-60 HLA class I bound
peptides were identiﬁed in mesenchymal cell lines
compared to 400-500 peptides in epithelial counter-
parts. IFNg as well as 5-aza-2’-deoxycytidine treat-
ment was able to revive immunoproteasome
expression and hence restored repertoire of HLA class
I bound peptides in deﬁcient mesenchymal cells.
Induced expression of immunoproteasome and hence
HLA class I bound peptides also lead to signiﬁcantly
enhanced CD8þ T cell mediated cytotoxicity (p<0.01)
in mesenchymal cells compared to non-induced con-
trols. Our ﬁndings point towards a mechanism of
immune evasion of cells with a mesenchymal pheno-
type and strategies to overcome their immune evasion
through induction of the immunoproteasome or tar-
geting the limited repertoire of peptides presented in
common by these cell types.
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Several lines of evidence indicated that the anti-diabetic
agent metformin may have signiﬁcant anti-tumoractivity. This is an economical and effective anti-diabetic
agent used by more than 120 million patients world-
wide and is well-tolerated by non-diabetics too. Met-
formin is believed to mediate anti-tumor action through
blockade of mitochondrial OxPhos complex I and in-
duction of a stage of mild metabolic stress that activates
the AMP-activated kinase pathway (AMPK), an enzyme
with tumor suppressor activity.
We showed that AMPK is a sensor of both metabolic
and genotoxic stress that mediates cell cycle arrest and
tumor suppression. Our pre-clinical translational and
retrospective clinical studies suggested that targeting
metabolism in NSCLC with metformin enhances NSCLC
radio-sensitivity and could improve outcomes in locally
advanced NSCLC.
NRG-LU001 (NCT02186847) is an NCI-CTEP funded
trial that opened to accrual in August 2014. It is designed
to examine speciﬁcally whether metformin could radio-
chemo-sensitize NSCLC in locally advanced stage III (A
and B) patients. Its primary outcome is 1 year progres-
sion free survival (PFS) and secondary outcomes
include: overall survival (OAS); time to local-regional
progression (LRP); time to distant metastasis (DM);
Chemo-RT toxicity; biospecimen collection for biomarker
analysis. This will include: circulating serum and blood
cell biomarkers of metformin activity and tumor
response and tumor biomarkers such as tumor histology,
TP53, LKB1 and K-Ras mutation status.
NRG-LU001 target accrual is 168 patients with 1:1
randomization to either chemo-radiotherapy (CRT) alone
vs CRT and metformin of 2000mg daily given only during
cytotoxic therapy. This includes concurrent CRT for 6
weeks followed by 6 weeks of consolidation chemo-
therapy treatment. Chemotherapy, in both the concurrent
and the consolidate phase of this study is the carboplatin-
paclitaxel doublet, while patients receive standard chest
RT of 60Gy in 30 fractions. Sample size calculations are
based on observed 1-year PFS of 50% (RTOG-0617 data)
and an expected improvement of 15% with metformin.
With 152 analyzable patients this study will have 85%
power to detect this improvement. The number is
increased to 168 to allow 10% rate of ineligibility.
LU001 is currently open in 52 centers across North
America. This is one of the ﬁrst clinical trials investi-
gating the potential of metabolism modulating agents to
enhance chemo-RT responses in locally advanced
NSCLC. It is expected to provide initial efﬁcacy results
for this agent and assist in the investigation and
development of circulating and tumor biomarkers of
metformin action and sensitivity. If positive this study
will allow us to design rationally future phase III
studies to examine deﬁnitively the role of metformin in
this setting.
